In preparations for Brexit, the EMA has redistributed the UK’s product portfolio to other EU members and is not allocating any centralised marketing authorisation applications to the MHRA. We take a closer look at this and the consequences it may have…
Brexit
Over the weekend, The Guardian reported on the end of Britain’s role in evaluating new medicines for sale across the European Union as a result of Brexit. Although, this is not necessarily completely unexpected in terms of the potential impact of Brexit on healthcare, it has still been seen as a huge blow by industry and its ramifications potentially highly costly.